Guided Therapeutics Inc (GTHP) — SEC Filings
Guided Therapeutics Inc (GTHP) — 12 SEC filings. Latest: 10-Q (Nov 13, 2025). Includes 6 10-Q, 2 10-K, 2 8-K.
View Guided Therapeutics Inc on SEC EDGAR
Overview
Guided Therapeutics Inc (GTHP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: GUIDED THERAPEUTICS INC (GTHP) reported a net loss of $1.978 million for the nine months ended September 30, 2025, an increase from a net loss of $1.765 million in the same period of 2024. Revenue from devices and disposables significantly increased to $177,000 for the nine months ended September 30
Sentiment Summary
Across 12 filings, the sentiment breakdown is: 3 bearish, 9 neutral. The dominant filing sentiment for Guided Therapeutics Inc is neutral.
Filing Type Overview
Guided Therapeutics Inc (GTHP) has filed 6 10-Q, 2 10-K, 2 8-K, 2 SC 13G/A with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (12)
| Date | Form | Description | Risk |
|---|---|---|---|
| Nov 13, 2025 | 10-Q | GTHP's Losses Widen Amid Cash Burn, Despite Revenue Jump | high |
| Aug 14, 2025 | 10-Q | GUIDED THERAPEUTICS' Losses Widen Amid Soaring Expenses | high |
| May 15, 2025 | 10-Q | Guided Therapeutics Files Q1 2025 10-Q, Evaluates Tax Disclosures | medium |
| Mar 31, 2025 | 10-K | Guided Therapeutics Files 2024 10-K: Net Loss of $10.49M | high |
| Dec 23, 2024 | 8-K | Guided Therapeutics Enters Material Definitive Agreement | medium |
| Nov 14, 2024 | 10-Q | Guided Therapeutics Reports Q3 2024 Results | medium |
| Sep 27, 2024 | 8-K | Guided Therapeutics Enters Material Definitive Agreement | medium |
| Aug 14, 2024 | 10-Q | Guided Therapeutics Reports Q2 2024 Results, Discloses Agreements | medium |
| May 14, 2024 | 10-Q | Guided Therapeutics Inc. Files 10-Q for Q1 2024 | medium |
| Mar 28, 2024 | 10-K | Guided Therapeutics Inc. Files 2023 Annual Report on Form 10-K | medium |
| Feb 20, 2024 | SC 13G/A | SC 13G/A Filing | |
| Feb 14, 2024 | SC 13G/A | SC 13G/A Filing |
Risk Profile
Risk Assessment: Of GTHP's 10 recent filings, 3 were flagged as high-risk, 7 as medium-risk, and 0 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $177,000 |
| Net Income | -$1,978,000 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $87,000 |
| Operating Margin | N/A |
| Total Assets | $903,000 |
| Total Debt | $6,549,000 |
Key Executives
- Mr. James
- Dr. Imhoff
- Mr Blumberg
- Dr. Cartwright
- Dr. Faupel
- Mr. Fowler
- Richard Blumberg
- Mr. Bill Wells
Industry Context
Guided Therapeutics Inc. operates in the medical device sector, specifically focusing on solutions for women's health. The industry is characterized by rigorous regulatory approval processes, significant R&D investment, and competition from established players and innovative startups. Trends include a growing demand for minimally invasive procedures and personalized medicine.
Top Tags
10-Q (3) · financials (3) · Biotechnology (2) · Medical Devices (2) · Small Cap (2) · Dilution (2) · material-definitive-agreement (2) · Loss-Making (1) · High Debt (1) · Cash Burn (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $1.978M | Increased from $1.765M in prior year, indicating worsening profitability. |
| Revenue (Devices & Disposables) | $177K | Significant increase from $6K in prior year, showing sales growth. |
| Cash and Cash Equivalents | $87K | Decreased by 77.6% from $388K, highlighting severe liquidity issues. |
| Total Liabilities | $6.549M | Increased from $6.267M, adding to financial burden. |
| Total Stockholders' Deficit | $(5.646)M | Worsened from $(4.889)M, reflecting accumulated losses. |
| Interest Expense | $433K | Increased from $247K, indicating higher debt servicing costs. |
| General and Administrative Expenses | $1.287M | Increased from $974K, contributing to higher operating costs. |
| Common Stock Shares Outstanding | 83,599,156 | Increased from 65,131,000, indicating significant dilution. |
| Sales - devices and disposables | $117K | Significant increase from $6K in prior year, showing some product traction. |
| Total Operating Expenses | $1.255M | Increased from $1.017M, outpacing revenue growth and contributing to wider losses. |
| Net Cash Used in Operating Activities | $500K | Indicates rapid cash burn, unsustainable without significant new financing. |
| Total Assets | $940K | Significantly lower than liabilities, indicating a weak balance sheet. |
| Accumulated Deficit | $155.028M | Massive historical losses, reflecting a long-standing inability to achieve profitability. |
| Common Shares Outstanding | 78,971 | Increased from 65,131 shares, indicating dilution from equity financing. |
| Par Value | $0.001 | Common Stock par value |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Guided Therapeutics Inc (GTHP)?
Guided Therapeutics Inc has 12 recent SEC filings from Feb 2024 to Nov 2025, including 6 10-Q, 2 10-K, 2 8-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GTHP filings?
Across 12 filings, the sentiment breakdown is: 3 bearish, 9 neutral. The dominant sentiment is neutral.
Where can I find Guided Therapeutics Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Guided Therapeutics Inc (GTHP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Guided Therapeutics Inc?
Key financial highlights from Guided Therapeutics Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for GTHP?
The investment thesis for GTHP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Guided Therapeutics Inc?
Key executives identified across Guided Therapeutics Inc's filings include Mr. James, Dr. Imhoff, Mr Blumberg, Dr. Cartwright, Dr. Faupel and 3 others.
What are the main risk factors for Guided Therapeutics Inc stock?
Of GTHP's 10 assessed filings, 3 were flagged high-risk, 7 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Guided Therapeutics Inc?
Forward guidance and predictions for Guided Therapeutics Inc are extracted from SEC filings as they are enriched.